Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy Cancer Trial
Portfolio Pulse from Vandana Singh
Lyell Immunopharma Inc (NASDAQ:LYEL) shares dropped significantly after the company reported a patient death in its Phase 1 trial of LYL797, a CAR-T cell therapy. The trial showed some positive results but also highlighted serious adverse events, including a Grade 5 respiratory failure.
June 26, 2024 | 6:44 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Lyell Immunopharma's shares fell sharply by 35.9% following the announcement of a patient death in its Phase 1 trial of LYL797. The trial showed some positive clinical activity but also serious adverse events, including a Grade 5 respiratory failure.
The significant drop in share price is directly linked to the negative news of a patient death in the trial, which raises concerns about the safety profile of LYL797. Despite some positive clinical activity, the adverse events overshadow the trial's outcomes.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100